Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coherus Oncology (CHRS) Cash from Financing Activities (2016 - 2025)

Coherus Oncology (CHRS) has disclosed Cash from Financing Activities for 12 consecutive years, with $8.1 million as the latest value for Q4 2025.

  • Quarterly Cash from Financing Activities rose 3398.27% to $8.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$273.7 million through Dec 2025, down 46.39% year-over-year, with the annual reading at -$273.7 million for FY2025, 46.39% down from the prior year.
  • Cash from Financing Activities hit $8.1 million in Q4 2025 for Coherus Oncology, up from $2000.0 in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $54.3 million in Q2 2023 to a low of -$281.5 million in Q2 2025.
  • Historically, Cash from Financing Activities has averaged -$14.2 million across 5 years, with a median of $994000.0 in 2021.
  • Biggest five-year swings in Cash from Financing Activities: skyrocketed 7434.67% in 2023 and later crashed 445.93% in 2024.
  • Year by year, Cash from Financing Activities stood at $1.5 million in 2021, then surged by 343.38% to $6.6 million in 2022, then crashed by 94.45% to $366000.0 in 2023, then crashed by 36.89% to $231000.0 in 2024, then surged by 3398.27% to $8.1 million in 2025.
  • Business Quant data shows Cash from Financing Activities for CHRS at $8.1 million in Q4 2025, $2000.0 in Q3 2025, and -$281.5 million in Q2 2025.